Trinity Biotech plc
Trinity Biotech plc (TRIB) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
trib · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Trinity Biotech plc (TRIB) measures how much investors pay for each dollar of the company's trailing earnings. TRIB's current PE ratio of N/A is calculated by dividing its stock price of $0.68 by its TTM earnings per share of -$2.01.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 10 fiscal years · Front-end computedMinQ1 · 25%18.9x
MedianQ3 · 75%53.4x
Max
At N/A, TRIB's current P/E is lower than in 0% of its annual fiscal year readings over the past 10 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Diagnostics & Research · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Trinity Biotech plcYou TRIB | $7M | N/A | — | -$2.01 |
 Advanced Biomed Inc. Common Stock ADVB | $4M | N/A | — | -$0.09 |
 BioNexus Gene Lab Corp. BGLC | $4M | N/A | — | -$1.61 |
 Check-Cap Ltd. CHEK | $11M | N/A | — | -$4.30 |
 Evogene Ltd. EVGN | $5M | N/A | — | -$1.08 |
 GBS Inc. GBS | $0M | N/A | — | -$2.00 |
 Marker Therapeutics, Inc. MRKR | $16M | N/A | — | -$0.79 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-2.02 | — | |
2024-12-31 FY2024 | — | $-1.77 | — | |
2023-12-31 FY2023 | — | $-3.14 | — | |
2022-12-31 FY2022 | — | $-6.08 | — | |
2021-12-31 FY2021 | 34.16x | $0.21 | — | |
2020-12-31 FY2020 | — | $-1.53 | — | |
2019-12-31 FY2019 | — | $-0.97 | — | |
2018-12-31 FY2018 | 20.03x | $0.57 | — | |
2017-12-31 FY2017 | — | $-9.31 | — | |
2016-12-31 FY2016 | — | $-21.91 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Trinity Biotech plc (TRIB) measures how much investors pay for each dollar of the company's trailing earnings. TRIB's current PE ratio of N/A is calculated by dividing its stock price of $0.68 by its TTM earnings per share of -$2.01.
Frequently asked questions
TRIB pe ratio · 6 questionsTRIB's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.68 and TTM EPS of -$2.01. Data sourced from Financial Modeling Prep via TRIB's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Trinity Biotech plc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09